12:00 AM
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Enbrel etanercept: Began Phase II/III testing

Immunex Corp. (IMNX), Seattle, Wash.
Product: Enbrel etanercept
Business: Cardiovascular
Therapeutic category: Immune modulation
Target: TNF
Description: Recombinant p75 TNF receptor linked to the Fc portion of human IgGI...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >